A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome
نویسندگان
چکیده
This study aimed to evaluate the efficacy and safety of Ganoderma lucidum for the treatment of hyperglycaemia and other cardiovascular risk components of metabolic syndrome using a prospective, double-blind, randomised, placebo-controlled trial. Eighty-four participants with type 2 diabetes mellitus and metabolic syndrome were randomised to one of three intervention groups: Ganoderma lucidum, Ganoderma lucidum with Cordyceps sinensis, or placebo. The dosage was 3 g/day of Ganoderma lucidum, with or without Cordyceps sinensis, for 16 weeks. The primary outcome measure was blood glucose (glycosylated haemoglobin [HbA1c] and fasting plasma glucose [FPG]); a number of secondary outcome measures were also tested. Data from the two intervention groups were combined. The combined intervention had no effect on any of the primary (baseline-adjusted difference in means: HbA1c = 0.13%, 95% CI [-0.35, 0.60], p = 0.60; FPG = 0.03 mmol/L, 95% CI [-0.90, 0.96], p = 0.95) or secondary outcome measures over the course of the 16-week trial, and no overall increased risk of adverse events with either active treatment. Evidence from this randomised clinical trial does not support the use of Ganoderma lucidum for treatment of cardiovascular risk factors in people with diabetes mellitus or metabolic syndrome. This Clinical Trial was registered with the Australian New Zealand Clinical Trials Registry on November 23, 2006. Trial ID: ACTRN12606000485538 and can be accessed here: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=81705.
منابع مشابه
The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial
The Effect of Curcumin on Some of Traditional and Non-Traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial Abstract Numerous interventional studies in clinical and preclinical setting stated that intake of curcumin may provide protection against cardiovascular disease. The aim of this trial was investigation of curcumin efficiency on some cardiovas...
متن کاملThe Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial
The Effect of Curcumin on Some of Traditional and Non-Traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-Blind, Placebo-Controlled Trial Abstract Numerous interventional studies in clinical and preclinical setting stated that intake of curcumin may provide protection against cardiovascular disease. The aim of this trial was investigation of curcumin efficiency on some cardiovas...
متن کاملStudy of potential cardioprotective effects of Ganoderma lucidum (Lingzhi): results of a controlled human intervention trial.
Previous studies have suggested that Lingzhi (Ganoderma lucidum) has antioxidant effects and possibly beneficial effects on blood pressure, plasma lipids and glucose, but these have not been confirmed in subjects with mild hypertension or hyperlipidaemia. The objective of the present study was to assess the cardiovascular, metabolic, antioxidant and immunomodulatory responses to therapy with Li...
متن کاملEffects of Omega-3 Supplementation on Blood Pressure in Patients with Type 2 Diabetes: A Double-Blind, Placebo-Controlled Clinical Trial
Objective: Type 2 diabetes mellitus (DM-2) is a chronic and progressive metabolic disorder known as a serious threatening condition in the individual and society. Type 2 diabetes mellitus is known as the major cause of cardiovascular diseases (CVD). Contradictory evidences about the effect of omega-3 fatty acids on CVD risk factors, particularly hypertension. The aim of this study was to determ...
متن کاملA double-blind, placebo-controlled evaluation of Vitex agnus castus premenstrual syndrom
The objective of this study was to assess the effect of Vitex agnus castus (VACS) extract in the alleviation of the symptoms of premenstrual syndrome. The study was designed as a double-blind, placebo controlled trial in two parallels groups (15 patients each). Treatment phase lasted 3 consequent menstrual cycles (2*30 drops/day=1.8 ml of VACS) or placebo. For assessment of the efficacy visual ...
متن کامل